Martine Reynaud-Gaubert

Martine Reynaud-Gaubert

Auto-generated profile, based on publicly available information

Martine Reynaud-Gaubert

Department of Respiratory Medicine and Lung Transplantation, Adult Cystic Fibrosis Center Aix Marseille University, Assistance Publique–Hôpitaux de Marseille, Hôpital Nord, Marseille, France

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
ABAthénaïs Boucly
Athénaïs Boucly
LSLaurent SAVALE
Laurent SAVALE
XJXavier Jaïs
Xavier Jaïs
Fabrice BAUERFabrice BAUER
Fabrice BAUER
EBEmmanuel Bergot
Emmanuel Bergot
OSOlivier Sitbon
Olivier Sitbon
Rationale: The relationship between the initial treatment strategy and survival in pulmonary arterial hypertension (PAH) remains uncertain. Objectives: To evaluate the long-term survival of patients with PAH categorized according to the initial treatment strategy. Methods: A retrospective analysis of incident patients with idiopathic, heritable, or anorexigen-induced PAH enrolled in the French Pulmonary Hypertension Registry (January 2006 to December 2018) was conducted. Survival was assessed according to the initial strategy: monotherapy, dual therapy, or triple-combination therapy (two oral medications and a parenteral prostacyclin). Measurements and Main Results: Among 1,611 enrolled patients, 984 were initiated on monotherapy, 551 were initiated on dual therapy, and 76 were initiated on triple therapy. The triple-combination group was younger and had fewer comorbidities but had a higher mortality risk. The survival rate was higher with the use of triple therapy (91% at 5 yr) as compared with dual therapy or monotherapy (both 61% at 5 yr) (P < 0.001). Propensity score matching of age, sex, and pulmonary vascular resistance also showed significant differences between triple therapy and dual therapy (10-yr survival, 85% vs. 65%). In high-risk patients (n = 243), the survival rate was higher with triple therapy than with monotherapy or dual therapy, whereas there was no difference between monotherapy and double therapy. In intermediate-risk patients (n = 1,134), survival improved with an increasing number of therapies. In multivariable Cox regression, triple therapy was independently associated with a lower risk of death (hazard ratio, 0.29; 95% confidence interval, 0.11–0.80; P = 0.017). Among the 148 patients initiated on a parenteral prostacyclin, those on triple therapy had a higher survival rate than those on monotherapy or dual therapy. Conclusions: Initial triple-combination therapy that includes parenteral prostacyclin seems to be associated with a higher survival rate in PAH, particularly in the youngest high-risk patients.

1 July 2024 in Annals of the American Thoracic Society
Verified
Journal Article
Closed access
PNEUMOLOGIE BurgelPNEUMOLOGIE Burgel
PNEUMOLOGIE Burgel
JPJean-Louis Paillasseur
Jean-Louis Paillasseur
IDIsabelle Durieu
Isabelle Durieu
MRMartine Reynaud-Gaubert
Martine Reynaud-Gaubert
RHRebecca Hamidfar
Rebecca Hamidfar
CMClémence Martin
Clémence Martin
Rationale: Limited data exist on the safety and effectiveness of elexacaftor-tezacaftor-ivacaftor (ETI) in people with cystic fibrosis (pwCF) and advanced lung disease. Objectives: To evaluate the effects of ETI in an unselected population of pwCF and advanced lung disease. Methods: A prospective observational study, including all adults aged 18 years and older with percentage predicted forced expiratory volume in 1 second (ppFEV1) ⩽ 40 who initiated ETI from December 2019 to June 2021 in France, was conducted. PwCF were followed until August 8, 2022. Results: ETI was initiated in 434 pwCF with a median ppFEV1 of 30 (interquartile range, 25–35), including 27 with severe cystic fibrosis liver disease and 183 with diabetes. PwCF were followed for a median of 587 (interquartile range, 396–728) days after ETI initiation. Discontinuation of ETI occurred in 12 (2.8%) pwCF and was due mostly to lung transplantation (n = 5) or death (n = 4). Absolute increase in ppFEV1 by a mean of +14.2% (95% confidence interval, 13.1–15.4%) occurred at 1 month and persisted throughout the study. Increase in ppFEV1 in the youngest age quartile was almost twice that of the oldest quartile (P < 0.001); body mass index < 18.5 kg/m2 was found in 38.6% at initiation versus 11.3% at 12 months (P = 0.0001). Increases in serum concentrations of vitamins A and E, but not 25-hydroxy vitamin D3, were observed. Significant reductions in the percentages of pwCF using oxygen therapy, noninvasive ventilation, nutritional support, and inhaled and systemic therapies (including antibiotics) were observed; insulin was discontinued in 12% of patients with diabetes. Conclusions: ETI is safe in pwCF and advanced lung disease, with multisystem pulmonary and extrapulmonary benefits.

4 April 2024 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
ABAlexandre Brudon
Alexandre Brudon
MLMarie Legendre
Marie Legendre
AMArthur Mageau
Arthur Mageau
JBJulien Bermudez
Julien Bermudez
PBPhilippe Bonniaud
Philippe Bonniaud
TNthe OrphaLung network
the OrphaLung network
Background: Several rare surfactant-related gene (SRG) variants associated with interstitial lung disease are suspected to be associated with lung cancer, but data are missing. We aimed to study the epidemiology and phenotype of lung cancer in an international cohort of SRG variant carriers.Methods: We conducted a cross-sectional study of all adults with SRG variants in the OrphaLung network and compared lung cancer risk with telomere-related gene (TRG) variant carriers.Results: We identified 99 SRG adult variant carriers (SFTPA1(n=18),SFTPA2(n=31),SFTPC(n=24),ABCA3(n=14) andNKX2-1(n=12)), including 20 (20.2%) with lung cancer (SFTPA1(n=7),SFTPA2(n=8),SFTPC(n=3),NKX2-1(n=2) andABCA3(n=0)). Among SRG variant carriers, the odds of lung cancer was associated with age (OR 1.04, 95% CI 1.01–1.08), smoking (OR 20.7, 95% CI 6.60–76.2) andSFTPA1/SFTPA2variants (OR 3.97, 95% CI 1.39–13.2). Adenocarcinoma was the only histological type reported, with programmed death ligand-1 expression ≥1% in tumour cells in three samples. Cancer staging was localised (I/II) in eight (40%) individuals, locally advanced (III) in two (10%) and metastatic (IV) in 10 (50%). We found no somatic variant eligible for targeted therapy. Seven cancers were surgically removed, 10 received systemic therapy, and three received the best supportive care according to their stage and performance status. The median overall survival was 24 months, with stage I/II cancers showing better survival. We identified 233 TRG variant carriers. The comparative risk (subdistribution hazard ratio) for lung cancer in SRG patientsversusTRG patients was 18.1 (95% CI 7.1–44.7).Conclusions: The high risk of lung cancer among SRG variant carriers suggests specific screening and diagnostic and therapeutic challenges. The benefit of regular computed tomography scan follow-up should be evaluated.

6 September 2016 in Allergy
Verified
Journal Article
Closed access
PDF file
VJVitte Joana
Vitte Joana
TRT. Romain
T. Romain
ACA. Carsin
A. Carsin
MGM. Gouitaa
M. Gouitaa
NBN. Stremler-Le Bel
N. Stremler-Le Bel
JMJean-Louis Mege
Jean-Louis Mege

1 May 2006 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
Emilie MamessierEmilie Mamessier
Emilie Mamessier
FMFrançois Milhe
François Milhe
MBMonique Badier
Monique Badier
PTPascal Alexandre Thomas
Pascal Alexandre Thomas
AMAntoine Magnan
Antoine Magnan
MRMartine Reynaud-Gaubert
Martine Reynaud-Gaubert

28 February 2012 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
BCB. Crestani
B. Crestani
JCJ. Chapron
J. Chapron
BWB. Wallaert
B. Wallaert
EBE. Bergot
E. Bergot
PDP. Delaval
P. Delaval
XDX. Duval
X. Duval